Esperion Therapeutics, Inc. – NASDAQ:ESPR

Add to watchlist

$2.03

-0.24

-10.95%

Market closed

Open in about 10 hours

-9.16%

month

-9.16%

quarter

-19.43%

year

Market Cap	433.49M
Enterprise value	227.29M

P/E	-0.4
EV/Sales	3.01
EV/EBITDA	-1.28
Price/Sales	1.20
Price/Book	-0.28
PEG ratio	N/A
EPS	-0.97

Revenue	229.74M
EBITDA	-34.68M
Income	-86.50M
Revenue Q/Q	466.13%
Revenue Y/Y	183.74%

Profit margin	-309.58%
Oper. margin	-237.83%
Gross margin	64.27%
EBIT margin	-237.83%
EBITDA margin	-15.1%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Esperion Therapeutics Stock Forecast

M Q Y

Last Year

Potential upside: 294.03%

Analysts Price target
Financials & Ratios estimates

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Profit margin
Jun 2023	25.78M	-49.93M	-193.65%
Sep 2023	33.96M	-41.25M	-121.43%
Dec 2023	32.25M	-56.34M	-174.71%
Mar 2024	137.73M	61.02M	44.3%

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Debt to assets
Jun 2023	234626000	606.60M	258.54%
Sep 2023	221305000	631.30M	285.27%
Dec 2023	205796000	660.79M	321.09%
Mar 2024	373060000	667.35M	178.89%

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Cash Flow
Jun 2023	-24.75M	17.5M	809K
Sep 2023	-19.32M	0	-4.31M
Dec 2023	-37.05M	0	4.47M
Mar 2024	53.82M	-73K	90.60M

Esperion Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Esperion Therapeutics
Employees

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Employee count
Aug 2023	199
Sep 2023	199
Oct 2023	199
Nov 2023	199
Dec 2023	199
Jan 2024	199
Feb 2024	199
Mar 2024	240
Apr 2024	240
May 2024	240
Jun 2024	240
Jul 2024	240

Esperion Therapeutics
Hedge Funds Holdings Q3 2022

95.19% +4.42%

of ESPR is owned by hedge funds

135 +1

hedge funds hold ESPR stock

60.18M +4.85M

shares is hold by hedge funds

ESPR hedge funds holdings changes

Esperion Therapeutics
Insider Trading

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Insider trades (number of shares)
Period	Buy	Sel
May 2024	0	192
Jun 2024	0	5825
Jul 2024	0	1025
Aug 2024	0	211
Sep 2024	0	17158
Oct 2024	0	107
Nov 2024	0	197
Dec 2024	0	17926

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	17 Dec 2024	HALLADAY BENJAMIN officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,245	$2.42	$7,866
Sale	17 Dec 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	2,234	$2.43	$5,426
Sale	17 Dec 2024	KOENIG SHELDON L. director, officer..	Common Stock	12,447	$2.47	$30,694
Sale	19 Nov 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	197	$2.17	$427
Sale	17 Oct 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	107	$2.12	$227
Sale	17 Sep 2024	KOENIG SHELDON L. director, officer..	Common Stock	14,550	$1.8	$26,132
Sale	17 Sep 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	2,608	$1.78	$4,650
Sale	19 Aug 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	211	$1.95	$411
Sale	17 Jul 2024	WARREN ERIC officer: Chief Commercial Officer officer: Chief Commercial Officer	Common Stock	108	$2.59	$279
Sale	17 Jul 2024	FOODY JOANNE M. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	917	$2.6	$2,383

ESPR insider trading transactions

Esperion Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 7 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 1 Aug 2023	Q2 2023 Earnings Call Transcript

ESPR earnings call transcripts

Esperion Therapeutics
Executives

Insider	Age	Since	Compensation
Mr. Richard B. Bartram (1982) Chief Financial Officer & Corporation Sec.	43		$529,750
Mr. Sheldon L. Koenig (1966) Pres, Chief Executive Officer & Director	59		$507,640

Esperion Therapeutics
Latest News

Wednesday, 18 December 2024
07:00	Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions	globenewswire.com
Friday, 13 December 2024
06:00	Esperion Announces $210 Million Convertible Debt Financing	globenewswire.com
Thursday, 12 December 2024
08:00	Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel	globenewswire.com
Sunday, 8 December 2024
07:43	Will The Long Awaited Breakout For Esperion Therapeutics Hold?	seekingalpha.com
Tuesday, 3 December 2024
11:10	ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada	zacks.com
Monday, 18 November 2024
10:30	Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024	globenewswire.com
Wednesday, 13 November 2024
02:08	Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy	seekingalpha.com
Friday, 8 November 2024
16:15	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 7 November 2024
12:00	Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y	zacks.com
08:11	Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
06:00	Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update	globenewswire.com
Monday, 4 November 2024
08:00	Esperion to Participate in Upcoming Jefferies London Healthcare Conference	globenewswire.com
Thursday, 31 October 2024
11:05	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release	zacks.com
Thursday, 24 October 2024
08:00	Esperion to Report Third Quarter 2024 Financial Results on November 7	globenewswire.com
Wednesday, 25 September 2024
16:30	Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 11 September 2024
12:30	Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?	zacks.com
Tuesday, 3 September 2024
08:00	Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)	globenewswire.com
Monday, 26 August 2024
08:00	Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Monday, 19 August 2024
09:10	Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs	seekingalpha.com
Friday, 16 August 2024
04:09	Esperion Therapeutics: Strategically Positioned To Grow	seekingalpha.com
Monday, 12 August 2024
21:50	Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript	seekingalpha.com
12:47	Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year	zacks.com
08:11	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
06:00	Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update	globenewswire.com
Wednesday, 7 August 2024
16:30	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	globenewswire.com
Monday, 5 August 2024
11:01	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	zacks.com
Tuesday, 16 July 2024
08:00	New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries	globenewswire.com
Friday, 28 June 2024
07:00	Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility	globenewswire.com
Thursday, 13 June 2024
14:31	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget	investorplace.com
Tuesday, 11 June 2024
10:00	3 Penny Stocks to Buy if You Want to Spend Less and Earn More	investorplace.com

Frequently Asked Questions (FAQ)

What's the price of Esperion Therapeutics stock today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $2.03.
When is Esperion Therapeutics's next earnings date?

Unfortunately, Esperion Therapeutics's (ESPR) next earnings date is currently unknown.
Does Esperion Therapeutics pay dividends?

No, Esperion Therapeutics does not pay dividends.
How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of 433.49M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 54.14% to 116.33M US dollars.
What is Esperion Therapeutics's stock symbol?

Esperion Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ESPR".
What is Esperion Therapeutics's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Esperion Therapeutics?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Esperion Therapeutics's key executives?
Esperion Therapeutics's management team includes the following people:
- Mr. Richard B. Bartram Chief Financial Officer & Corporation Sec.(age: 43, pay: $529,750)
- Mr. Sheldon L. Koenig Pres, Chief Executive Officer & Director(age: 59, pay: $507,640)
How many employees does Esperion Therapeutics have?

As Jul 2024, Esperion Therapeutics employs 240 workers.
When Esperion Therapeutics went public?

Esperion Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 26 Jun 2013.
What is Esperion Therapeutics's official website?

The official website for Esperion Therapeutics is esperion.com.
Where are Esperion Therapeutics's headquarters?

Esperion Therapeutics is headquartered at 3891 Ranchero Drive, Ann Arbor, MI.
How can i contact Esperion Therapeutics?

Esperion Therapeutics's mailing address is 3891 Ranchero Drive, Ann Arbor, MI and company can be reached via phone at +7 348873903.
What is Esperion Therapeutics stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Esperion Therapeutics in the last 12 months, the avarage price target is $8. The average price target represents a 294.03% change from the last price of $2.03.

Esperion Therapeutics, Inc.

esperion.com

Exchange:

NASDAQ

Full time employees:

240

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

+7 348873903

3891 Ranchero Drive
Ann Arbor, MI 48108

CIK: 0001434868
ISIN: US29664W1053
CUSIP: 29664W105